GSBTD
ABBV icon

Glenview State Bank Trust Department’s AbbVie ABBV Stock Holding History

Glenview State Bank Trust Department’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$4.12M Sell
36,526
-217
-0.6% -$24.4K 1.26% 23
2021
Q1 		$3.98M Buy
36,743
+277
+0.8% +$29.6K 1.29% 22
2020
Q4 		$3.91M Sell
36,466
-2,560
-7% -$246K 1.36% 22
2020
Q3 		$3.42M Buy
39,026
+1,810
+5% +$170K 1.3% 22
2020
Q2 		$3.65M Buy
37,216
+527
+1% +$46.4K 1.51% 19
2020
Q1 		$2.79M Buy
36,689
+175
+0.5% +$14.9K 1.34% 23
2019
Q4 		$3.23M Buy
36,514
+200
+0.6% +$16.6K 1.24% 25
2019
Q3 		$2.75M Hold
36,314
– – 1.11% 28
2019
Q2 		$2.64M Buy
36,314
+125
+0.3% +$9.82K 1.1% 29
2019
Q1 		$2.92M Buy
36,189
+1,110
+3% +$90.8K 1.25% 26
2018
Q4 		$3.23M Buy
35,079
+444
+1% +$39K 1.56% 24
2018
Q3 		$3.28M Hold
34,635
– – 1.43% 25
2018
Q2 		$3.21M Buy
34,635
+670
+2% +$65.4K 1.48% 24
2018
Q1 		$3.21M Sell
33,965
-50
-0.1% -$5.49K 1.51% 22
2017
Q4 		$3.29M Buy
34,015
+375
+1% +$35.3K 1.52% 24
2017
Q3 		$2.99M Hold
33,640
– – 1.45% 27
2017
Q2 		$2.44M Hold
33,640
– – 1.24% 30
2017
Q1 		$2.19M Sell
33,640
-50
-0.1% -$3.14K 1.13% 30
2016
Q4 		$2.11M Buy
33,690
+825
+3% +$50.4K 1.15% 30
2016
Q3 		$2.07M Sell
32,865
-43
-0.1% -$2.78K 1.16% 31
2016
Q2 		$2.04M Sell
32,908
-958
-3% -$58.4K 1.18% 31
2016
Q1 		$1.93M Sell
33,866
-263
-0.8% -$14.7K 1.17% 30
2015
Q4 		$2.02M Buy
34,129
+200
+0.6% +$11.5K 1.25% 29
2015
Q3 		$1.85M Hold
33,929
– – 1.24% 28
2015
Q2 		$2.28M Sell
33,929
-4,600
-12% -$300K 1.4% 26
2015
Q1 		$2.25M Sell
38,529
-1,400
-4% -$84.6K 1.36% 25
2014
Q4 		$2.61M Hold
39,929
– – 1.57% 24
2014
Q3 		$2.31M Sell
39,929
-5,750
-13% -$319K 1.41% 26
2014
Q2 		$2.58M Sell
45,679
-500
-1% -$26.2K 1.55% 23
2014
Q1 		$2.37M Sell
46,179
-1,500
-3% -$75.8K 1.47% 25
2013
Q4 		$2.52M Buy
+47,679
New +$2.34M 1.58% 24

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Glenview State Bank Trust Department's ABBV Position: Q2 2021 in Review

Glenview State Bank Trust Department reduced its AbbVie (ABBV) stake by 0.59% in Q2 2021, selling an estimated $24.4K and leaving 36,526 shares worth $4.12M. The position accounts for 1.26% of the portfolio, ranked #23.

Glenview State Bank Trust Department first reported a position in ABBV in Q4 2013 and has held it in 31 quarters since. 2,677 funds tracked by Wall St. Rank hold ABBV as of Q2 2021.

  • Glenview State Bank Trust Department held 36,526 shares of AbbVie worth $4.12M as of Q2 2021.
  • Glenview State Bank Trust Department sold 217 AbbVie shares in Q2 2021, an estimated $24.4K.
  • AbbVie made up 1.26% of Glenview State Bank Trust Department's portfolio in Q2 2021, its #23 holding.
  • Glenview State Bank Trust Department first reported a position in AbbVie in Q4 2013 and has held it in 31 quarters since.
  • 2,677 funds tracked by Wall St. Rank held AbbVie as of Q2 2021.

Based on Glenview State Bank Trust Department's 13F filing for Q2 2021, filed 28 Jul 2021.